4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug Administration (FDA) approval, with the first two implantations at Piedmont Heart Hospital in Atlanta. The implantations were conducted by Christopher Meduri, M.D., Vivek Rajagopal, M.D., and Mani Vannan, M.D. The study will evaluate the TriCinch Coil System in 15 patients across seven centers in the U.S.
Siemens Healthineers announced the U.S. Food and Drug Administration (FDA) clearance of the Cios Spin, a new mobile C-arm that delivers precise 3-D images for intraoperative quality assurance.
November 5, 2018 — The U.S. Food and Drug Administration (FDA) is evaluating recent reports of Getinge's Maquet ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S. launch of Mynx Control Vascular Closure ...
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to adopt a newer, less invasive technique, according to a new study, published Oct. 31 in JAMA Cardiology from Weill Cornell Medicine. When hospitals have a high caseload of both, they are likely to achieve the best patient outcomes for those who undergo the newer procedure.
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the BVA-100 blood volume analyzer showed statistically significantly reduced 30-day readmission and 30-day and one-year mortality rates. The study, published in the Journal of the American College of Cardiology - Heart Failure,1 compared the experimental group to propensity-matched controls.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Digital health company Planet Intelligent recently launched the ExMedicus Smartwatch, what it calls the world’s first health smartwatch with biometric technology that monitors overall health, heart health and physical wellness.
Fujifilm SonoSite Inc. announced the launch of its redesigned SonoSite Institute, a comprehensive online educational resource dedicated to empowering and educating healthcare providers about point-of-care ultrasound (POCUS). Based on the feedback of current global users, the enhanced website now features an improved user experience, easier-to-locate content and reconfigured learning paths.
A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood clots, without increasing the risk of serious bleeding or triggering an autoimmune response. These conclusions are drawn from new research in the American Heart Association’s journal Hypertension.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
November 1, 2018 — Daxor Corp. has entered an agreement with CHF Solutions to explore clinical synergies between Daxor’s ...
November 1, 2018 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...
Example of GE Healthcare’s FetalHQ software for the ultrasound imaging of fetal hearts. The new tool runs on GE ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Vygon, an international group specialized in single-use medical devices, and French company Sonoscanner announced the design and development of the VysionXS, a new ultrasound scanner dedicated to vascular access catheterization guidance.
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (evolocumab) in patients with established cardiovascular disease by kidney function. In line with previous FOURIER subgroup analyses, these results further demonstrate Repatha's efficacy in reducing not only low-density lipoprotein cholesterol (LDL-C) levels, but also the relative risk for major cardiovascular events such as heart attack and stroke, in high-risk patients including those with mild-to-moderate chronic kidney disease (CKD).1-4 In these patients (N=4,443), absolute reductions tended to be greater in the risk for the composite secondary endpoint which included cardiovascular death, heart attack or stroke. Adverse events were similar across patients regardless of CKD stage and consistent with the Repatha known safety profile.
Recent statin and medication advances have led some researchers to suggest surgical treatments for carotid stenosis should be limited to symptomatic patients – primarily those who have already had a stroke or TIA. However, a new study published in the Journal of Vascular Surgery questions whether medical therapy is a sufficient stroke-reduction strategy.